Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).
      QxMD      Google Scholar   
Citation:
Ann Surg Oncol vol 31 (10) 7033-42
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
14
Parents:
3911   4162  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882; UG1CA189850, UG1CA233290, UG1CA233329, U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                 
Networks:
LAPS-NY016, LAPS-TX035, NORTHWELL, OH070   
Study
Alliance-A021501
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: